Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,341 result(s) found. Displaying page 1,549 of 2,218.
    «« First « Previous 1545  1546  1547  1548  1549  1550  1551  1552  1553  Next» Last»»
    EudraCT Number: 2004-001688-23 Sponsor Protocol Number: NA17598C Start Date*: 2004-10-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerability of 12 months of once daily treatment with 1 mg of RO3300074 in patients with symptomatic em...
    Medical condition: symptomatic emphysema secondary to alpha-1-antitrypsin deficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-004181-37 Sponsor Protocol Number: B9371039 Start Date*: 2023-02-03
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A TICK-BORNE ENCEPHALITIS VACCINE IN HEALTHY JAPANESE PARTICIPANTS 1 YEAR OF AGE AND OLDER
    Medical condition: Active immunization to prevent tick borne encephalitis (TBE)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-008258-21 Sponsor Protocol Number: NV20536 eu Start Date*: 2009-03-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegas...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) ES (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001337-40 Sponsor Protocol Number: BXCL501-105 Start Date*: 2021-10-05
    Sponsor Name:BioXcel Therapeutics, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER
    Medical condition: Subject that meets DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder, or other specified/unspecified schizophrenia spectrum and/or other psychotic disorders OR Subjec...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    20.0 10037175 - Psychiatric disorders 10039629 Schizophrenia childhood LLT
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2004-004612-23 Sponsor Protocol Number: TV-3326/201 Start Date*: 2005-04-13
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: A multi-center, randomized, double-blind, placebo-controlled, sequential cohort designed, escalating dose study to assess the tolerability, safety and maximal tolerated dose (MTD) of Ladostigil in ...
    Medical condition: Patients with probable Alzheimer's Disease (AD) diagnosis according to NINCDS-ADRDA and DSM–IV criteria, who suffer from mild to moderate dementia with a Mini Mental State Examination (MMSE) of 15-26
    Disease: Version SOC Term Classification Code Term Level
    7.0 10001897 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004073-31 Sponsor Protocol Number: 2021/1001 Start Date*: 2022-01-17
    Sponsor Name:University Medical Center Groningen
    Full Title: Treating microalbuminuria over 24 weeks in subjects with or without type 2 diabetes or hypertension
    Medical condition: Microalbuminuria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10027525 Microalbuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004478-24 Sponsor Protocol Number: OV101-18-002 Start Date*: 2020-06-05
    Sponsor Name:Ovid Therapeutics Inc.
    Full Title: An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals with Angelman Syndrome (ELARA)
    Medical condition: Angelman Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10049004 Angelman's syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000249-38 Sponsor Protocol Number: R118439 Start Date*: 2019-01-25
    Sponsor Name:University of Manchester
    Full Title: Phase II trial of interleukin-1 receptor antagonist in intracerebral haemorrhage: BLOcking the Cytokine IL-1 in ICH
    Medical condition: intracerebral haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10022753 Intracerebral haemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-003709-33 Sponsor Protocol Number: AIO-HEP-0116 Start Date*: 2017-05-04
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies
    Medical condition: advanced, unresectable and metastatic cholangio- and gallbladder carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077846 Cholangiocarcinoma metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017634 Gallbladder neoplasms malignant HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051667 Metastases to gallbladder PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017614 Gallbladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001632-19 Sponsor Protocol Number: MVT-601-3102 Start Date*: 2017-12-01
    Sponsor Name:Myovant Sciences GmbH
    Full Title: SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Ac...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) CZ (Completed) PL (Completed) GB (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-000615-24 Sponsor Protocol Number: 20121903114 Start Date*: 2014-03-11
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Tacrolimus disposition in pediatric transplantation: influence of age, genetic polymorphisms, intestinal and hepatic relative contribution on pharmacokinetics, in relationship with clinical outco...
    Medical condition: PEDIATRIC LIVER TRANSPLANTATION
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001139-22 Sponsor Protocol Number: POPH Start Date*: 2011-06-29
    Sponsor Name:Medizinische Universität Graz, Klin. Abteilung für Gastroenterologie und Hepatologie
    Full Title: AMBRISENTAN FOR TREATMENT OF PORTOPULMONARY HYPERTENSION (POPH): A PILOT STUDY
    Medical condition: Portopulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome HPS are present in a considerable number of patients with compensated cirrhosis. Treatment of PoPH with ambrisentan is well tolerated...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10067281 Portopulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016829-34 Sponsor Protocol Number: 06644329988 Start Date*: 2010-07-28
    Sponsor Name:Medizinische Universität Graz, Klinische Abteilung für Thorax -u. Hyperbare Chirurgie
    Full Title: Influence of perioperative administration of diclovenac-natrium/orfendadrincitrate on the recurrence rate of surgically treated spontaneous pneumothorax
    Medical condition: Spontaneous pneumothorax
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002678-10 Sponsor Protocol Number: GF22002 Start Date*: 2023-03-07
    Sponsor Name:Ginefiv
    Full Title: Protocol with progestin-primed ovarian stimulation (PPOS) starting on day 5 versus protocol with progestin-primed ovarian stimulation (PPOS) in a conventional regimen from the start of the ovaria...
    Medical condition: Number of MII oocytes obtained in both groups
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003913-12 Sponsor Protocol Number: 22/589-EC_M. Start Date*: 2023-03-07
    Sponsor Name:COMPLUTENSE UNIVERSITY OF MADRID
    Full Title: Diode laser and photodynamic therapy Versus Ciclopirox Hydroxypropyl Chitosan. Randomised controlled clinical trial.
    Medical condition: Onychomycosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003861-39 Sponsor Protocol Number: GLUCOTAVI Start Date*: 2023-03-07
    Sponsor Name:JUAN MIGUEL RUIZ NODAR
    Full Title: Glucocorticoid treatment in patients undergoing TAVI to reduce the incidence of atrioventricular block and pacemaker implantation
    Medical condition: aortic stenosis
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004749-40 Sponsor Protocol Number: PEDMet 2006-1 Start Date*: 2006-11-20
    Sponsor Name:Pediatrics
    Full Title: Glucose metabolism in patients with neurological/neuromuscular diseases.
    Medical condition: Patients with neurological/neuromuscular diseases
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002912-73 Sponsor Protocol Number: AL-JVC-05-01 Start Date*: 2005-08-02
    Sponsor Name:University Hospitals Leuven
    Full Title: An Open Label Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of 15 mg Anecortave Acetate for Depot Suspension Combined with Verteporfin Therapy in Patients with Exudati...
    Medical condition: Age Related Macular Degeneration with Retino-choroidal Anastomosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002801-36 Sponsor Protocol Number: Can-201 Start Date*: 2023-03-08
    Sponsor Name:Cantex Pharmaceuticals Inc.
    Full Title: A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined with Conventional Concurrent Radiation and Temozolomide in Patients with Newly...
    Medical condition: Newly diagnosed glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001939-38 Sponsor Protocol Number: NIVINIHO Start Date*: 2018-04-18
    Sponsor Name:LYSARC
    Full Title: A prospective phase II study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with classical Hodgkin Lymphoma and coexisting medical conditions
    Medical condition: patients aged 61 years and older, with classical Hodgkin lymphoma and coexisting medical conditions
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1545  1546  1547  1548  1549  1550  1551  1552  1553  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 15:22:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA